Malcolm Weir
Amministratore Delegato presso Heptares Therapeutics Ltd.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Charles Peter Downes | M | 71 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Kenneth Buechler | M | 70 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Richard Reece | M | 58 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Gebhard Schertler | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Beverly Lybrand | F | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Ed Hulme | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Michelle Joanne West | F | 55 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Helen Watson | M | 39 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Luciane Vieira de Mello Rigden | M | 60 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Frank Sargent | M | 54 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Stefan Roberts | M | 57 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Martin Richard Pool | M | 52 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
David Pye | M | 59 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Barry Kenny | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Dominika Teresa Gruszka | M | 40 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Joanne Edwards | M | 53 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Anne Dell | F | 74 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Chris Cargill | M | 40 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 5 anni |
Kong Hung Lee | M | 75 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Miles Congreve | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 16 anni |
Manos Topoglidis | M | 49 |
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | - |
Tim Tasker | M | 71 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Tomohiro Tohyama | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Fiona Hamilton Marshall | M | 59 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Michael Steinmetz | M | 75 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Richard Henderson | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Roger Perlmutter | M | 71 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
John Berriman | M | 76 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 8 anni |
Daniel S. Grau | M | 57 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
John Bradshaw | M | 60 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 7 anni |
Atul Pande | M | 69 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Roberto Solari | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
David McGibney | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Declan Doogan | M | 72 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Christopher G. Tate | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Peter Bains | M | 65 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 36 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Malcolm Weir
- Contatti personali